- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 37/00 - Drugs for immunological or allergic disorders
Patent holdings for IPC class A61P 37/00
Total number of patents in this class: 9162
10-year publication summary
|
356
|
490
|
638
|
658
|
611
|
743
|
702
|
623
|
555
|
365
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Mondobiotech Laboratories AG | 311 |
290 |
| Bristol-myers Squibb Company | 4729 |
151 |
| F. Hoffmann-La Roche AG | 7836 |
133 |
| Novartis AG | 10263 |
116 |
| Incyte Corporation | 1072 |
73 |
| Genentech, Inc. | 4099 |
71 |
| Hoffmann-La Roche Inc. | 3783 |
65 |
| Boehringer Ingelheim International GmbH | 4493 |
58 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3337 |
47 |
| Merck Patent GmbH | 5725 |
45 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | 712 |
43 |
| Takeda Pharmaceutical Company Limited | 2715 |
42 |
| Janssen Pharmaceutica N.V. | 3171 |
41 |
| The Regents of the University of California | 20720 |
38 |
| Glaxosmithkline Intellectual Property Development Limited | 776 |
38 |
| Glaxo Group Limited | 4370 |
37 |
| AstraZeneca AB | 2818 |
37 |
| Pfizer Inc. | 3384 |
37 |
| Jiangsu Hengrui Medicine Co., Ltd. | 694 |
32 |
| Centre National de La Recherche Scientifique | 11016 |
31 |
| Other owners | 7737 |